Real-time feed of open-market stock purchases and sales by corporate executives, directors, and 10% beneficial owners verified against official SEC Form 4 filings.
| Recency | Stock | Insider | Role | Type | Shares | Price | Total Value | SEC Form 4 | Actions |
|---|---|---|---|---|---|---|---|---|---|
| 3d ago 2026-09-18 |
Walmart Inc.
|
Nicholas Christopher James | President | arrow_downward SELL | -1,395 | $106.83 | $149.0K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
Walmart Inc.
|
Nicholas Christopher James | President | arrow_downward SELL | -1,505 | $106.49 | $160.3K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
Walmart Inc.
|
Furner John R. | CEO | arrow_downward SELL | -6,045 | $106.84 | $645.9K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
Walmart Inc.
|
Furner John R. | CEO | arrow_downward SELL | -7,080 | $106.50 | $754.0K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
UNITED THERAPEUTICS Corp
|
MAHON PAUL A | EVP & GENERAL COUNSEL | arrow_downward SELL | -320 | $501.58 | $160.5K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
UNITED THERAPEUTICS Corp
|
MAHON PAUL A | EVP & GENERAL COUNSEL | arrow_downward SELL | -125 | $500.80 | $62.6K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
UNITED THERAPEUTICS Corp
|
MAHON PAUL A | EVP & GENERAL COUNSEL | arrow_downward SELL | -1,160 | $499.75 | $579.7K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
UNITED THERAPEUTICS Corp
|
MAHON PAUL A | EVP & GENERAL COUNSEL | arrow_downward SELL | -843 | $498.74 | $420.4K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
UNITED THERAPEUTICS Corp
|
MAHON PAUL A | EVP & GENERAL COUNSEL | arrow_downward SELL | -1,400 | $497.54 | $696.6K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
UTHR
🐋 Whale
UNITED THERAPEUTICS Corp
|
MAHON PAUL A | EVP & GENERAL COUNSEL | arrow_downward SELL | -2,873 | $496.58 | $1.43M | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
UNITED THERAPEUTICS Corp
|
MAHON PAUL A | EVP & GENERAL COUNSEL | arrow_downward SELL | -1,579 | $495.97 | $783.1K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
UNITED THERAPEUTICS Corp
|
ROTHBLATT MARTINE A | CEO | arrow_downward SELL | -160 | $501.60 | $80.3K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
UNITED THERAPEUTICS Corp
|
ROTHBLATT MARTINE A | CEO | arrow_downward SELL | -468 | $500.09 | $234.0K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
UNITED THERAPEUTICS Corp
|
ROTHBLATT MARTINE A | CEO | arrow_downward SELL | -332 | $499.10 | $165.7K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
UNITED THERAPEUTICS Corp
|
ROTHBLATT MARTINE A | CEO | arrow_downward SELL | -151 | $497.79 | $75.2K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
UNITED THERAPEUTICS Corp
|
ROTHBLATT MARTINE A | CEO | arrow_downward SELL | -1,953 | $497.17 | $971.0K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
UTHR
🐋 Whale
UNITED THERAPEUTICS Corp
|
ROTHBLATT MARTINE A | CEO | arrow_downward SELL | -2,182 | $496.21 | $1.08M | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
UNITED THERAPEUTICS Corp
|
ROTHBLATT MARTINE A | CEO | arrow_downward SELL | -1,905 | $495.11 | $943.2K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
UNITED THERAPEUTICS Corp
|
ROTHBLATT MARTINE A | CEO | arrow_downward SELL | -1,750 | $494.34 | $865.1K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
UNITED THERAPEUTICS Corp
|
ROTHBLATT MARTINE A | CEO | arrow_downward SELL | -599 | $493.22 | $295.4K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
Target Hospitality Corp.
|
Schrenk Troy C. | Officer | arrow_upward BUY | +5,907 | $21.16 | $125.0K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
TELA Bio, Inc.
|
Capper Joseph H | Director | arrow_upward BUY | +25,000 | $1.22 | $30.5K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
TELA Bio, Inc.
|
Capper Joseph H | Director | arrow_upward BUY | +50,000 | $1.17 | $58.3K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
TEEKAY CORP LTD
|
Locke Simon Heidi | Director | arrow_downward SELL | -400 | $14.93 | $6.0K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
Sony Group Corp
|
Ito Yasuhiro | Officer | arrow_downward SELL | -9,000 | $24.29 | $218.6K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
Skye Bioscience, Inc.
|
5AM Partners VII, LLC | 10% Owner | arrow_downward SELL | -1,285 | $1.91 | $2.5K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
Skye Bioscience, Inc.
|
5AM Partners VII, LLC | 10% Owner | arrow_downward SELL | -32,607 | $1.91 | $62.3K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
Skye Bioscience, Inc.
|
Schwab Andrew J. | Director | arrow_downward SELL | -1,285 | $1.91 | $2.5K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
Skye Bioscience, Inc.
|
Schwab Andrew J. | Director | arrow_downward SELL | -32,607 | $1.91 | $62.3K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
SEMTECH CORP
|
Cardenuto Rodolpho C | Director | arrow_downward SELL | -5,321 | $165.00 | $878.0K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
RVTY
🐋 Whale
REVVITY, INC.
|
Vohra Tajinder S | Please See Remarks | arrow_downward SELL | -7,330 | $140.88 | $1.03M | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
QUICKLOGIC Corp
|
SAXE TIMOTHY | SR. VP AND CTO | arrow_downward SELL | -10,364 | $10.21 | $105.9K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
QUICKLOGIC Corp
|
Faith Brian C | CEO | arrow_downward SELL | -17,255 | $10.21 | $176.2K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
QUICKLOGIC Corp
|
Nader Elias | CFO | arrow_downward SELL | -8,291 | $10.21 | $84.7K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
PubMatic, Inc.
|
Kumar Mukul | President | arrow_downward SELL | -8,000 | $16.78 | $134.2K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
Proto Labs Inc
|
Schumacher Daniel | CFO | arrow_downward SELL | -4,900 | $85.21 | $417.5K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
Proto Labs Inc
|
Schumacher Daniel | CFO | arrow_downward SELL | -100 | $85.00 | $8.5K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
PALVELLA THERAPEUTICS, INC.
|
Goin Kathleen | COO | arrow_downward SELL | -1,654 | $153.24 | $253.5K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
PALVELLA THERAPEUTICS, INC.
|
Goin Kathleen | COO | arrow_downward SELL | -989 | $152.36 | $150.7K | open_in_new Form 4 | |
| 3d ago 2026-09-18 |
PALVELLA THERAPEUTICS, INC.
|
Goin Kathleen | COO | arrow_downward SELL | -1,659 | $151.16 | $250.8K | open_in_new Form 4 |
Under Section 16(a) of the Securities Exchange Act of 1934, corporate insiders—executives, directors, and beneficial owners holding greater than 10% of any registered equity class—must report changes in stock ownership within two business days. Not all filings carry equal predictive value. Tickzen automatically categorizes transactions using the official SEC Table I code matrix:
| SEC Code | Transaction Type | Capital Outlay | Signal Direction | Predictive Significance & Institutional Rationale |
|---|---|---|---|---|
| Code P | Open-Market Purchase | Discretionary (Personal Cash) | ▲ High Bullish | The insider commits their own capital to buy shares at current market prices. Strongest positive conviction signal. |
| Code S | Open-Market Sale | Discretionary (Disposition) | ▼ Variable / Caution | Discretionary disposition of shares. Often executed for tax planning, estate diversification, or pre-set Rule 10b5-1 plans; heavy clustered selling warrants caution. |
| Code A | Grant or Award | Non-Discretionary (Equity Comp) | ● Neutral | Restricted Stock Units (RSUs) or performance shares granted by compensation committees. Reflects compensation, not independent buying. |
| Code M | Option Exercise | Contractual Conversion | ● Neutral / Plan | Conversion of stock options into shares, commonly paired with an immediate cashless open-market sale (Code S) to pay exercise fees and taxes. |
| Code F | Tax Withholding | Mandatory Administrative | ● Neutral | Automatic surrender of shares to the issuing company to pay statutory income tax liabilities upon equity vesting. |
| Code G | Bona Fide Gift | Non-Market Transfer | ● Neutral | Charitable contribution or private transfer of shares to family trusts, non-profit institutions, or estate planning vehicles. |
When 3 or more distinct corporate insiders purchase company stock within a 10-day window, academic studies show a statistically significant abnormal return over the subsequent 3 to 12 months compared to solitary executive purchases.
Chief Executive Officers (CEO) and Chief Financial Officers (CFO) possess daily operational oversight of sales pipelines and cost structures. Their discretionary purchases carry a much higher predictive signal than passive 10% hedge fund allocations.
